Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Miscellaneous

This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).
Miscellaneous
II
Moots, Paul
NCT03962543
VICCNEU1997

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: